EXAGEN INC. XGN

Healthcare SIC 8071 - Services-Medical Laboratories NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Medical and Diagnostic Laboratories › Medical Laboratories derived Nasdaq

We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.

Last close 7.27 2026-10-23
Market cap $176.1M 2026-06-30 share count
52-week range 2.59 - 12.23

Valuation FY2025 figures against the last close

P/S2.6x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.93

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $66.6M$55.6M$52.5M$45.6M$48.3M$42.0M$40.4M$32.4M—
Cost of revenue $27.8M$22.5M$23.1M$24.2M$20.6M$16.6M$18.8M$15.4M—
Gross profit $38.8M$33.1M$29.5M$21.3M$27.7M$25.4M$21.6M$17.1M—
R&D $6.3M$5.4M$4.9M$9.9M$7.2M$3.6M$2.2M$2.1M—
SG&A $46.6M$41.4M$47.4M$52.0M$44.5M$37.0M$28.7M$19.7M—
Total operating expenses $52.9M$46.7M$52.3M$91.6M$72.4M$57.2M$49.7M$37.3M—
Operating income -$14.1M-$13.6M-$22.8M-$46.1M-$24.1M-$15.2M-$9.3M-$4.9M—
Interest expense $4.3M$2.2M$2.3M$2.4M$2.6M$2.6M$3.5M$2.9M—
Pre-tax income -$19.9M-$15.1M-$23.7M-$47.1M-$26.7M-$16.6M-$12.0M-$8.0M—
Income tax $51.0K$12.0K$33.0K$282.0K$175.0K$79.0K$25.0K$58.0K—
Net income -$20.0M-$15.1M-$23.7M-$47.4M-$26.9M-$16.7M-$12.0M-$8.0M—
EPS, basic -0.93-0.83-1.34-2.77-1.68-1.32———
EPS, diluted -0.93-0.83-1.34-2.77-1.68-1.32-8.46-293.34—
Shares, diluted (wtd. avg.) 21.6M18.2M17.7M17.1M16.0M12.6M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $32.2M$22.0M$36.7M$62.6M$99.5M$57.5M$72.2M$13.3M$11.3M
Receivables $10.9M$7.8M$6.6M$6.1M$9.7M$8.9M$5.7M$6.0M—
Total current assets $48.9M$36.5M$47.8M$72.6M$112.7M$70.5M$81.2M$21.3M—
Property, plant and equipment ———$8.2M$4.8M$2.1M$1.4M$1.6M—
Goodwill ———$0$5.5M$5.5M$5.5M$5.5M—
Total assets $58.0M$44.7M$56.9M$86.2M$123.4M$78.4M$88.3M$28.9M—
Accounts payable $4.2M$4.1M$3.1M$3.0M$2.5M$3.0M$1.5M$1.3M—
Short-term debt $643.0K$423.0K$264.0K$190.0K$0————
Total current liabilities $14.2M$13.5M$11.9M$9.6M$9.3M$8.8M$5.9M$9.0M—
Long-term debt $22.3M$19.8M$19.2M$28.8M$27.5M$26.7M$25.9M$24.6M—
Total liabilities $40.6M$35.1M$34.2M$43.8M$38.5M$36.5M$32.7M$35.6M—
Retained earnings -$314.3M-$294.3M-$279.2M-$255.5M-$208.1M-$181.3M-$164.6M-$152.6M—
Total equity $17.4M$9.5M$22.7M$42.5M$84.9M$41.8M$55.7M-$112.0M-$96.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow -$13.6M-$13.3M-$14.5M-$32.1M-$20.3M-$14.1M-$9.7M-$9.3M—
Depreciation and amortisation $2.1M$1.7M$2.2M$1.6M$900.0K$500.0K$600.0K$600.0K—
Stock-based compensation $2.2M$1.8M$3.6M$4.7M$4.7M$2.7M$572.0K$114.0K—
Capital expenditure $641.0K$515.0K$828.0K$4.3M$2.4M$455.0K$403.0K$199.0K—
Investing cash flow -$626.0K-$515.0K-$804.0K-$4.3M-$2.4M-$455.0K-$103.0K-$199.0K—
Financing cash flow $24.4M-$663.0K-$10.6M-$489.0K$64.7M-$97.0K$68.7M$11.4M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001274737-26-000020.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M Revenue, FY2018: 32.4M Gross profit, FY2018: 17.1M Net income, FY2018: -8M Revenue, FY2019: 40.4M Gross profit, FY2019: 21.6M Net income, FY2019: -12M Revenue, FY2020: 42M Gross profit, FY2020: 25.4M Net income, FY2020: -16.7M Revenue, FY2021: 48.3M Gross profit, FY2021: 27.7M Net income, FY2021: -26.9M Revenue, FY2022: 45.6M Gross profit, FY2022: 21.3M Net income, FY2022: -47.4M Revenue, FY2023: 52.5M Gross profit, FY2023: 29.5M Net income, FY2023: -23.7M Revenue, FY2024: 55.6M Gross profit, FY2024: 33.1M Net income, FY2024: -15.1M Revenue, FY2025: 66.6M Gross profit, FY2025: 38.8M Net income, FY2025: -20M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $32.4M $40.4M $42.0M $48.3M $45.6M $52.5M $55.6M $66.6M
Gross profit — $17.1M $21.6M $25.4M $27.7M $21.3M $29.5M $33.1M $38.8M
Net income — -$8.0M -$12.0M -$16.7M -$26.9M -$47.4M -$23.7M -$15.1M -$20.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8071

TickerCompanyMarket capP/ERevenue growth
NTRA Natera, Inc. $58.23B — 35.9%
DGX QUEST DIAGNOSTICS INC $26.70B 27.6x 11.8%
LH LABCORP HOLDINGS INC. $26.68B 31.4x 7.2%
GH Guardant Health, Inc. $22.69B — 32.9%
CAI Caris Life Sciences, Inc. $9.04B — 97.0%
GRAL GRAIL, Inc. $5.92B — 17.2%
RDNT RadNet, Inc. $5.54B — 11.5%
BLLN BillionToOne, Inc. $5.00B 769.8x 100.0%